The Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP) is unique in that it is the only CCOP focused solely on providing radiation (RT)-related symptom amelioration trials, as well as bringing state-of-the-art RT treatment trials to the CCOP community. The RTOG CCOP conducts trials that can only be accomplished in a RT specific group, such assessment of different fractionation schedules for the palliation of painful bone metastases, the use of stereotactic radiosurgery to palliate spinal metastases, and the use of hippocampal avoidance with RT treatment planning to minimize memory loss after whole brain RT for brain metastases. To meet our unique mission we have instituted significant strategic changes including new PI leadership;a lengthy evaluation of facilitators and barriers to concept development and patient accrual over the current grant period;a revised committee structure including a new Steering/Concept Review Committee to strengthen the science, increase our portfolio, and further engage the CCOPs and improve accrual. Objectives include: 1) provision of a cancer control research program to study interventions to prevent or manage symptoms, and the study of biological measures that will assist in earlier prediction of outcomes.
This aim i s focused on 4 research themes important to patients treated with RT: Protectants for Mucositis &Epithelial Injury;Neurocognition;Palliation &QoL;and Late Effects &Survivorship. 2) Provision of access to the full complement of clinical and translational protocols available through the RTOG to CCOP members, and 3) maintenance of an infrastructure and tools for conduct and assessment of the impact of RTOG cancer control studies. The CCOP has leveraged its NCI funding to help support these objectives by developing shared resources with the RTOG including a Translational Research Program, a Feasibility Review and Clinical Trials, Education and Recruitment Working Groups. Our past work, new vision and strategic changes will advance symptom management science and provide evidence for interventions that will ultimately improve the quality of survival for patients with cancer treated with RT.
The unique goals of the Radiation Therapy Oncology Group's (RTOG) Community Clinical Oncology Program (CCOP) are to reduce the burden of illness and death related to cancer through treatment with radiation therapy (RT), and to prevent or reduce RT treatment related side effects. The RTOG CCOP goal is to provide evidence for interventions that will ultimately improve the quality of life for cancer survivors treated with RT. 7
|Michaelson, M Dror; Hu, Chen; Pham, Huong T et al. (2017) A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). Int J Radiat Oncol Biol Phys 97:995-1001|
|Mirhadi, Amin J; Zhang, Qiang; Hanks, Gerald E et al. (2017) Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys 97:511-515|
|Wagner, Lynne I; Pugh, Stephanie L; Small Jr, William et al. (2017) Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Cancer 123:485-493|
|Chang, Susan M; Chakavarti, Arnab; Bell, Erica H (2017) Reply to letter on results of NRG Oncology RTOG 9813. Neuro Oncol 19:739|
|Hurwitz, Mark D; Harris, Jonathan; Sartor, Oliver et al. (2017) Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer 123:2489-2496|
|Zhang, Qiang; Freidlin, Boris; Korn, Edward L et al. (2017) Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials 14:48-58|
|Bell, Erica Hlavin; Pugh, Stephanie L; McElroy, Joseph P et al. (2017) Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. JAMA Oncol 3:784-792|
|Gilbert, Mark R; Pugh, Stephanie L; Aldape, Ken et al. (2017) NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. J Neurooncol 131:193-199|
|Doll, Corinne M; Moughan, Jennifer; Klimowicz, Alexander et al. (2017) Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. Int J Radiat Oncol Biol Phys 97:554-562|
|Pugh, Stephanie L; Wyatt, Gwen; Wong, Raimond K W et al. (2017) Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire-RTOG Modification. J Pain Symptom Manage 53:139-145.e2|
Showing the most recent 10 out of 316 publications